Trial Profile
A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2020
Price :
$35
*
At a glance
- Drugs Coronavirus vaccine-Zydus Cadila (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Zydus Lifesciences
- 04 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2020 New trial record